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patients (n = 6199) were HR-positive, whereas 14.2 % 
(n = 1030) were HR-negative. Overall, 85.3 % (n = 5285) 
of HR-positive patients received ET either alone or in com-
bination with chemotherapy (CHT) and/or trastuzumab. 
The majority of premenopausal patients received CHT plus 
ET (716 patients, 52.3 %). In postmenopausal patients, 
the most frequent systemic therapy was ET alone (2670 
patients, 55.3 %). Best overall survival (OS) was found 
in HER2-/HR-positive patients receiving CHT plus ET 
plus trastuzumab (7-year OS rate of 97.2 % in premeno-
pausal patients versus 86.9 % in postmenopausal patients). 
Premenopausal patients had a reduced benefit from addi-
tional CHT than postmenopausal patients. Premenopausal 
patients receiving only ET had a 7-year OS rate of 95.3 % 
compared to 92.7 % of patients receiving CHT plus ET. In 
contrast, postmenopausal patients treated with CHT plus 
ET had a 7-year OS rate of 84.0 % in comparison with 
Abstract 
Purpose Adjuvant endocrine therapy (ET) is indicated in 
patients with steroid hormone receptor (HR)-positive breast 
cancer. The aim of this study was to evaluate the quality 
of HR determination and adjuvant endocrine treatment of 
breast cancer patients in a large cohort of more than 7000 
women by analyzing data from a population-based regional 
cancer registry.
Methods Data from the Clinical Cancer Registry Regens-
burg (Bavaria, Germany) were analyzed. Female patients 
with primary, nonmetastatic invasive breast cancer who 
were diagnosed between 2000 and 2012 (n = 7421) were 
included. HR-status was available in 97.4 % (n = 7229) of 
the patients. This data set (n = 7229) was used for subse-
quent statistical analyses.
Results Since 2009, almost a complete rate of 99.6 % of 
analyzed HR-status was achieved. In sum, 85.8 % of the 
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those patients receiving only ET with a 7-year OS rate of 
81.7 %.
Conclusions Analysis of HR in patients with early breast 
cancer achieved a very high quality in recent years. The 
vast majority of HR-positive patients received ET, and this 
guideline-adherent use improved OS. Inverse effects of the 
CHT plus ET combination in premenopausal versus post-
menopausal patients and a still existing minority of patients 
not receiving guideline-adherent treatment should be fur-
ther investigated in future studies.
Keywords Endocrine therapy · Steroid hormone 
receptor · Breast cancer · Overall survival · Cancer registry
Abbreviations
ET  Endocrine therapy
HR  Hormone receptor
CHT  Chemotherapy
ER  Estrogen receptor
PR  Progesterone receptor
AIs  Aromatase inhibitors
OS  Overall survival
GnRH  Gonadotropin-releasing hormone
RCTs  Randomized controlled trials
IRS  Immunoreactive score
SD  Standard deviation
CI  Confidence interval
Introduction
In addition to surgery and irradiation as local therapies, 
almost all patients with early breast cancer receive adju-
vant systemic medical treatments. These may include three 
components: chemotherapy (CHT), endocrine therapy 
(ET), and antibody therapy. Provided that breast cancer 
tissue expresses estrogen (ER) and/or progesterone (PR) 
receptors, adjuvant ET is indicated (Melcher et al. 2012). 
Adjuvant treatment with tamoxifen or aromatase inhibi-
tors (AIs) leads to a reduction in both recurrence-free and 
overall survival (OS) (Early Breast Cancer Trialists’ Col-
laborative Group (EBCTCG) et al. 2005; Baum et al. 2002; 
Thürlimann et al. 2005). Current state of the art treatment 
for women with endocrine-responsive early breast cancer is 
an adjuvant ET for at least 5 years (Kreienberg et al. 2013; 
Untch et al. 2013; Lux et al. 2013). The type of ET depends 
on ovarian function. For premenopausal patients, the stand-
ard ET is 5 years of tamoxifen monotherapy (EBCTCG 
et al. 2005). A meta-analysis of the EBCTCG showed effi-
cacy of adjuvant tamoxifen for both pre- and postmeno-
pausal patients (EBCTCG et al. 2011). A further treatment 
option for premenopausal patients is the combination of 
tamoxifen with gonadotropin-releasing hormone (GnRH) 
analogs (Baum et al. 2006; Cuzick et al. 2007). Another 
approach in premenopausal women is ovarian function 
suppression combined with AIs, which was investigated in 
two recently published studies, the suppression of ovarian 
function trial (SOFT) and tamoxifen and exemestan trial 
(TEXT) trial (Pagani et al. 2014). Adjuvant treatment with 
exemestane plus ovarian suppression significantly reduced 
recurrence in premenopausal patients with HR-positive 
early breast cancer, as compared with tamoxifen plus ovar-
ian suppression (Pagani et al. 2014).
Large-scale randomized controlled trials (RCTs) inves-
tigated the use of AIs as either a substitute or add-on 
to tamoxifen and showed a superiority of the AIs over 
tamoxifen in postmenopausal patients (Baum et al. 2002; 
Thürlimann et al. 2009; Coombes et al. 2004; Goss et al. 
2003; Dowsett et al. 2010). Different strategies includ-
ing AIs are possible, e.g., upfront monotherapy or switch 
to an AI after 2–3 years of tamoxifen or switch to tamox-
ifen after 2–3 years of AIs, and extended adjuvant treat-
ment with an AI after 5 years of tamoxifen (Lux et al. 
2013; Kolberg et al. 2012). Currently, the prolongation of 
ET beyond 5 years is discussed. The adjuvant tamoxifen: 
longer against shorter trial (ATLAS) showed that for ER-
positive breast cancer patients continuing tamoxifen for up 
to 10 years rather than stopping at 5 years yielded a fur-
ther reduction in recurrence and mortality, particularly after 
year 10 (Davies et al. 2013). A meta-analysis involving 
29,138 patients and eight RCTs concluded that in ER-pos-
itive breast cancer patients extended ET beyond 5 years of 
tamoxifen significantly improved OS [OR 0.89; 95 % con-
fidence interval (CI) 0.80–0.99; P = 0.03], breast cancer-
specific survival (OR 0.78; 95 % CI 0.69–0.9; P = 0.0003), 
and relapse-free survival (OR 0.72; 95 % CI 0.56–0.92; 
P = 0.01) compared with 5 years of ET alone (Petrelli et al. 
2013). However, further follow-up of the included trials is 
needed to confirm these results.
Despite these encouraging findings from numerous 
RCTs and meta-analyses, data on the performance of ET 
under routine conditions are scarce. Thus, the aim of this 
study was to evaluate the routine quality of diagnosis and 
adjuvant endocrine treatment of steroid hormone receptor 
(HR)-positive breast cancer patients in a large cohort of 
more than 7000 patients by analyzing data from a popula-
tion-based regional cancer registry.
Methods
Database
In the present study, data from the Tumor Center Regens-
burg (Bavaria, Germany) were analyzed. This high-quality 
population-based regional cancer registry was founded 
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in 1991 and covers a population of more than 2.2 million 
people of Upper Palatinate and Lower Bavaria. Currently, 
follow-up data of 240,655 patients of all major cancer 
sites are available. Following a stringent protocol, this can-
cer registry obtains a cross-sectorial documentation of all 
breast cancer patients in the area (n = 10,152 patients diag-
nosed between 2000 and 2012). Information about diagno-
sis, course of disease, therapies, and long-term follow-up 
are documented. Patient data originate from the Univer-
sity Hospital Regensburg, 53 regional hospitals, and more 
than 1000 practicing doctors in the region. Based on medi-
cal reports, pathology, and follow-up records, these popu-
lation-based data are routinely being documented and fed 
into the cancer registry.
Cancer registration in Bavaria
In Bavaria, the law on the Bavarian Epidemiologic Cancer 
Registry (Gesetz über das bevölkerungsbezogene Kreb-
sregister Bayern-BayKRG, as amended from time to time) 
allows the continuous and uniform data acquisition and 
processing of cancer incidences by means of an epidemio-
logic cancer registry. The purpose of this law is to regulate 
cancer control and to improve data quality of cancer epide-
miology. The Bavarian Epidemiologic Cancer Registry has 
to provide anonymous data for scientific research.
Informed consent has to be given in accordance with 
the Declaration of Helsinki and is an indispensable pre-
condition for data storage. Any physician has to adequately 
inform the patients about the intended or performed trans-
mission of data to the registry. Patients also receive written 
information about these procedures. Each patient has the 
right to object data storage at any time. On the basis of this 
law, retrospective analyses of anonymous data require no 
additional ethics statement.
Inclusion and exclusion criteria
The present analysis included all female patients docu-
mented in the cancer registry with primary, nonmetastatic 
(M0) invasive breast cancer diagnosed between January 
2000 and December 2012 (13 years). Follow-up data up 
to July 2013 were analyzed. Exclusion criteria were male 
patients, ductal carcinoma in situ (DCIS), and distant 
metastases (Fig. 1).
Analysis of HR
Immunohistochemical determination of ER and PR was 
performed and quantified as the percentage of positivity of 
malignant cells and average intensity of coloration consist-
ent with defined standards (Prechtel and Prechtel 2001). 
Additionally, the immunoreactive score (IRS) according 
to Remmele and Stegner (1987) was calculated. In the 
last update of the German interdisciplinary S3 Guideline 
for Diagnosis, Treatment and Follow-up Care of Breast 
Cancer (updated version 07/2012, registry number 032-
045OL of Association of the Scientific Medical Societies, 
AWMF) (Kreienberg et al. 2013), cutoff definitions for 
the interpretation of results were modified and follow the 
current ASCO/CAP recommendations (Hammond et al. 
2010). Since that date, at least 1 % of positively marking 
malignant cells is sufficient for determination of HR-status 
as positive. Previously, at least 10 % positivity was neces-
sary. In the data set, HR-positivity is defined as ER+PR+, 
ER+PR− or ER−PR+. HR-negativity is defined as 
ER−PR−.
Quality assurance methods
Overall, six institutes of pathology were involved in these 
analyses. Consistency and quality control are ensured 
through various quality assurance methods including the 
certification/accreditation of the pathologies according to 
DIN EN ISO 9001, the participation in the German inter-
laboratory trials, and regular regional breast cancer-specific 
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Fig. 1  Scheme of data extraction
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Statistical analyses
Continuous data were expressed as means ± standard devi-
ations (SD) and categorical data as frequency counts and 
percentages. Baseline characteristics of patients were com-
pared between HR-status by Student’s t test for continuous 
variables and by Pearson’s Chi-square tests for categorical 
variables. OS was calculated from the date of cancer diag-
nosis to the date of death from any cause. Patients who 
were not dead or patients without follow-up were classi-
fied as censored. The impact of established prognostic fac-
tors (age, tumor size, nodal status, grading, HER2/neu, and 
menopausal status) and the extent of primary therapy on 
OS were assessed by means of a multivariable Cox regres-
sion analysis. Hazard ratios (HR) and corresponding 95 % 
CI were calculated and considered statistically significant if 
CI excluded 1.0. All reported P values were two-sided, and 
a P value of 0.05 was considered the threshold of statisti-
cal significance. Calculations were made with the software 
packages SPSS 22 (Chicago, EUA) and R (version 3.0.3).
Results
Analysis of patients’ characteristics
According to the ICD-10 classification, 7421 female 
patients with invasive, nonmetastatic breast cancer (C50) 
were extracted from the total data pool of breast tumor 
patients (Fig. 1). The HR-status was available in 97.4 % 
(7229 patients) (Table 1). In 2.6 % (192 patients), the 
HR-status was absent due to missing information in the 
medical reports or no analysis. Since 2009, almost a com-
plete rate of 99.6 % of analyzed HR-status was achieved. 
Only patients with noted HR-status were included for fur-
ther statistical evaluation. Hence, a total of 7229 breast 
cancer patients were considered for subsequent analy-
ses (Table 2). In total, 1684 patients (23.3 %) were pre-
menopausal and 5545 patients (76.7 %) were postmeno-
pausal. Mean age was 61 years (median 61 years, range 
21–97 years); 85.8 % of patients (n = 6199) were HR-
positive, whereas 14.2 % of patients (n = 1030) were 
HR-negative. Postmenopausal women were more likely to 
be HR-positive (n = 4830, 87.1 %) than premenopausal 
patients (n = 1369, 81.3 %). All common histopathologi-
cal parameters showed (highly) statistically significant dif-
ferences between HR-positive and HR-negative patients. 
High-grade (G3) tumors were rather associated with nega-
tive HR-status. In HR-negative patients, 73.0 % of tumors 
were high grade compared to 20.2 % of HR-positive 
tumors (P < 0.001). HR-positive patients were more likely 
to be HER2-negative (75.5 %) than HR-negative patients 
(60.6 %) (P < 0.001) (Table 2). Detailed description of HR-
status is shown in Table 3. The majority of patients were 
both ER- and PR-positive (73.9 %) in both premenopausal 
and postmenopausal patients.
Distribution of HR‑status across different pathologies
To evaluate the inter-laboratory consistency, we investi-
gated the distribution of patients in different institutes of 
pathology as well as the distribution of HR-status. A total 
Table 1  Time-dependent rates of hormone receptor (HR) analyses
HR-positive is defined as ER+PR+, ER+PR−, or ER−PR+
HR-negative is defined as ER−PR−




HR-status analyzed  
(n, %)
HR-positive (n, %) HR-negative (n, %)
2000 448 28 (6.3 %) 420 (93.7 %) 345 (82.1 %) 75 (17.9 %)
2001 472 16 (3.4 %) 456 (96.6 %) 401 (87.9 %) 55 (12.1 %)
2002 477 19 (4.0 %) 458 (96.0 %) 379 (82.8 %) 79 (17.2 %)
2003 536 10 (1.9 %) 526 (98.1 %) 466 (88.6 %) 60 (11.4 %)
2004 595 20 (3.4 %) 575 (96.6 %) 489 (85.0 %) 86 (15.0 %)
2005 585 8 (1.4 %) 577 (98.6 %) 471 (81.6 %) 106 (18.4 %)
2006 570 1 (0.2 %) 569 (99.8 %) 487 (85.6 %) 82 (14.4 %)
2007 603 34 (5.6 %) 569 (94.4 %) 492 (86.5 %) 77 (13.5 %)
2008 608 45 (7.4 %) 563 (92.6 %) 464 (82.4 %) 99 (17.6 %)
2009 721 3 (0.4 %) 718 (99.6 %) 624 (86.9 %) 94 (13.1 %)
2010 628 4 (0.6 %) 624 (99.4 %) 542 (86.9 %) 82 (13.1 %)
2011 579 2 (0.3 %) 577 (99.7 %) 513 (88.9 %) 64 (11.1 %)
2012 599 2 (0.3 %) 597 (99.7 %) 526 (88.1 %) 71 (11.9 %)
Total 7421 192 (2.6 %) 7229 (97.4 %) 6199 (85.8 %) 1030 (14.2 %)
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Table 2  Associations 
between HR and clinical and 
histopathological parameters
HR-positive is defined as ER+PR+, ER+PR−, or ER−PR+
HR-negative is defined as ER−PR−
a P value of t test or Pearson’s Chi-square test, respectively
Parameter HR-positive (n = 6199) HR-negative (n = 1030) Total (n = 7229) P valuea
Age (year), mean ± SD 62 ± 13 57 ± 14 61 ± 13 <0.001
Menopausal state, n (%)
 Premenopausal 1369 (22.1 %) 315 (30.6 %) 1684 (23.3 %) <0.001
 Postmenopausal 4830 (77.9 %) 715 (69.4 %) 5545 (76.7 %)
Histology, n (%)
 Ductal 4913 (79.3 %) 896 (87.0 %) 5809 (80.4 %) <0.001
 Lobular 876 (14.1 %) 28 (2.7 %) 904 (12.5 %)
 Other 410 (6.6 %) 106 (10.3 %) 516 (7.1 %)
Tumor size, n (%)
 pT0 27 (0.4 %) 31 (3.0 %) 58 (0.8 %) <0.001
 pT1 3385 (54.6 %) 435 (42.2 %) 3820 (52.8 %)
 pT2 2217 (35.8 %) 449 (43.6 %) 2666 (36.9 %)
 pT3 237 (3.8 %) 49 (4.8 %) 286 (4.0 %)
 pT4 301 (4.9 %) 56 (5.4 %) 357 (4.9 %)
 Unknown 32 (0.5 %) 10 (1.0 %) 42 (0.6 %)
Nodal status, n (%)
 pN0 3832 (61.8 %) 608 (59.0 %) 4440 (61.4 %) 0.032
 pN1 1534 (24.7 %) 249 (24.2 %) 1783 (24.7 %)
 pN2 425 (6.9 %) 93 (9.0 %) 518 (7.2 %)
 pN3 283 (4.6 %) 57 (5.5 %) 340 (4.7 %)
 Unknown 125 (2.0 %) 23 (2.2 %) 148 (2.0 %)
Grading, n (%)
 G1 1017 (16.4 %) 14 (1.4 %) 1031 (14.3 %) <0.001
 G2 3891 (62.8 %) 256 (24.9 %) 4147 (57.4 %)
 G3 1252 (20.2 %) 752 (73.0 %) 2004 (27.7 %)
 Unknown 39 (0.6 %) 8 (0.8 %) 47 (0.7 %)
HER2, n (%)
 Negative 4678 (75.5 %) 624 (60.6 %) 5302 (73.3 %) <0.001
 Positive 952 (15.4 %) 306 (29.7 %) 1258 (17.4 %)
 Unknown 569 (9.2 %) 100 (9.7 %) 669 (9.3 %)
Lymphatic invasion, n (%)
 Positive 1676 (27.0 %) 350 (34.0 %) 2026 (28.0 %) <0.001
 Negative 3024 (48.8 %) 430 (41.7 %) 3454 (47.8 %)
 Unknown 1499 (24.2 %) 250 (24.3 %) 1749 (24.2 %)
Vascular invasion, n (%)
 Positive 320 (5.2 %) 92 (8.9 %) 412 (5.7 %) <0.001
 Negative 4168 (67.2 %) 634 (61.6 %) 4802 (66.4 %)
 Unknown 1711 (27.6 %) 304 (29.5 %) 2015 (27.9 %)
Table 3  ER- and/or 
PR-expression
Premenopausal  
(n = 1684, 23 %)
Postmenopausal  
(n = 5545, 77 %)
Total (n = 7229, 100 %)
ER+PR+ 1206 (71.6 %) 4137 (74.6 %) 5343 (73.9 %)
ER+PR− 125 (7.4 %) 600 (10.8 %) 725 (10.0 %)
ER−PR+ 38 (2.3 %) 93 (1.7 %) 131 (1.8 %)
ER−PR− 315 (18.7 %) 715 (12.9 %) 1030 (14.2 %)
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of six institutions were involved in HR diagnostics. These 
analyzed samples from 133 to 1787 patients. The distri-
bution of HR-status across the different pathologies was 
homogenous which reflects the established quality assur-
ance methods in the Tumor Centre Regensburg. Regarding 
ER, 15 % of samples from patients (n = 826) had IRS 0, 
and 53 % (n = 2903) had IRS 12. With respect to PR, 24 % 
of patients (n = 1324) had IRS 0, and 28 % (n = 1506) 
had IRS 12. IRSs lying in between were underrepresented 
(Fig. 2).
Systemic therapies in HR‑positive patients
Overall, 5285 (85.3 %) of 6199 HR-positive patients 
received ET either alone or in combination with CHT 
and/or trastuzumab (Table 4). Thereby, the proportion of 
premenopausal and postmenopausal patients receiving 
ET was identical (85.8 % premenopausal versus 85.1 % 
postmenopausal).
The majority of premenopausal patients received CHT 
plus ET (716 patients, 52.3 %) and ET alone (343 patients, 
25.1 %), respectively. In postmenopausal patients, the most 
frequent systemic therapy was ET alone (2670 patients, 
55.3 %) followed by CHT plus ET (1255 patients, 26.0 %). 
The relatively large number of 614 HR-positive patients 
(9.9 %) received no adjuvant therapy at all (Table 4). Fur-
ther analyses regarding this revealed the following: In 
n = 368/614 (59.9 %) of these patients, an ET was planned 
but not started yet, n = 36 (5.9 %) of the patients declined 
an ET, and in 34.2 % of the cases, reasons for the nonuse 
could not be identified.
Analysis of type of ET in HR‑positive patients
Moreover, the type of ET in HR-positive patients was 
analyzed (Table 5). In 85.2 % of patients (n = 4504), the 
type of ET was documented. In pre- and in postmenopau-
sal patients, the most frequently applied ET was tamoxifen 
(66.8 %, n = 666 premenopausal versus 50.5 %, n = 1770 
postmenopausal patients). Furthermore, 20.0 % (n = 199) 
of premenopausal patients obtained tamoxifen plus GnRH 
and 8.7 % (n = 87) AIs alone. In sum, 46.3 % (n = 1625) 
of the postmenopausal patients received AIs alone. Overall, 
2.5 % (n = 112) of patients were treated with tamoxifen 
followed by AI.
Survival analyses in HR‑positive patients
To evaluate the effects of various systemic therapies, we 
compared the different treatment groups (Table 6). Pre-
menopausal patients generally showed better survival 
rates than postmenopausal patients. Best OS was found in 
HER2-/HR-positive patients receiving CHT plus ET plus 
trastuzumab in premenopausal as well as in postmeno-
pausal patients (7-year OS rate of 97.2 % in premenopau-
sal patients versus 86.9 % in postmenopausal patients). 
The effect of the (non-) use of trastuzumab on survival in 
HER2-positive breast cancer patients and its correlation 
with HR-status and ET has been previously shown in a 
study of our group in the same patient cohort (Inwald et al. 
2014). In HER2-positive patients (n = 1258), there was 
a significant difference in OS between HR-positive and 
HR-negative patients (7-year OS rate of 83.7 % in HR-
positive patients versus 76.0 % in HR-negative patients, 
P = 0.006).
Survival effects as a function of menopausal state
Application of CHT prior to ET led to different survival 
effects in both age groups (Figs. 3, 4). Premenopausal 
IRS-Score Estrogen receptor (N, %) Progesterone receptor (N,%)
0 826 (15%) 1324 (24%)
1 79 (1%) 185 (3%)
2 123 (2%) 338 (6%)
3 68 (1%) 165 (3%)
4 183 (3%) 471 (9%)
5 5 (0%) 4 (0%)
6 433 (8%) 631 (12%)
7 2 (0%) 1 (0%)
8 310 (6%) 195 (4%)
9 524 (10%) 587 (11%)
10 6 (0%) 5 (0%)
11 4 (0%) 4 (0%)
12 2903 (53%) 1506 (28%)
Total 5466 (100%) 5416 (100%)
Fig. 2  Distribution of IRS scores of ER and PR
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patients (Fig. 3) had a reduced benefit from additional 
CHT than postmenopausal patients (Fig. 4). Premeno-
pausal patients receiving only ET had a 7-year OS rate 
of 95.3 % compared to 92.7 % of patients receiving CHT 
plus ET. In contrast, postmenopausal patients treated with 
CHT plus ET had a 7-year OS rate of 84.0 % in compari-
son with those patients receiving only ET with a 7-year 
OS rate of 81.7 %. Depriving HR-positive patients ET and 
only administering CHT caused lower OS rates in both age 
groups than in the particular control group. Lowest OS of 
Table 4  Different systemic 
therapies in HR-positive 
patients
Premenopausal  
(n = 1369, 22.1 %)
Postmenopausal 
(n = 4830, 77.9 %)
Total (n = 6199, 100 %)
CHT + ET + Trastu-
zumab
115 (8.4 %) 170 (3.5 %) 285 (4.6 %)
CHT + Trastuzumab 14 (1.0 %) 18 (0.4 %) 32 (0.5 %)
ET + Trastuzumab 1 (0.1 %) 15 (0.3 %) 16 (0.3 %)
CHT + ET 716 (52.3 %) 1255 (26.0 %) 1971 (31.8 %)
ET 343 (25.1 %) 2670 (55.3 %) 3013 (48.6 %)
CHT 96 (7.0 %) 172 (3.6 %) 268 (4.3 %)
No adjuvant therapy 84 (6.1 %) 530 (11.0 %) 614 (9.9 %)
Table 5  Type of ET in 
HR-positive patients
Premenopausal  
(n = 1175, 22.2 %)
Postmenopausal  
(n = 4110, 77.8 %)
Total (n = 5285, 100 %)
Unknown 178 (15.1 %) 603 (14.7 %) 781 (14.8 %)
Known 997 (84.9 %) 3507 (85.3 %) 4504 (85.2 %)
 Tamoxifen 666 (66.8 %) 1770 (50.5 %) 2436 (54.1 %)
 Tamox-
ifen + GnRH
199 (20.0 %) 14 (0.4 %) 213 (4.7 %)
 Tamoxifen + AI 14 (1.4 %) 98 (2.8 %) 112 (2.5 %)
 AI 87 (8.7 %) 1625 (46.3 %) 1712 (38.0 %)
 GnRH 31 (3.1 %) – 31 (0.7 %)
Table 6  Overall survival rates 
categorized by menopausal 
status and adjuvant therapy
Premenopausal patients: n = 1354
Postmenopausal patients: n = 4797
Total: n = 6151
3-Year OS  
(%)
5-Year OS  
(%)
6-Year OS  
(%)
7-Year OS  
(%)
CHT + ET + Trastuzumab
 Premenopausal (n = 115, 8.5 %) 98.9 97.2 97.2 97.2
 Postmenopausal (n = 170, 3.5 %) 96.6 93.1 93.1 86.9
CHT + ET
 Premenopausal (n = 716, 52.9 %) 97.1 95.6 94.5 92.7
 Postmenopausal (n = 1255, 26.2 %) 95.9 89.9 87.0 84.5
ET
 Premenopausal (n = 343, 25.3 %) 99.0 96.9 96.5 95.3
 Postmenopausal (n = 2670, 55.7 %) 93.9 87.8 84.8 81.7
CHT
 Premenopausal (n = 96, 7.1 %) 92.7 83.7 77.6 77.6
 Postmenopausal (n = 172, 3.6 %) 80.5 75.9 74.9 72.4
No adjuvant therapy
 Premenopausal (n = 84, 6.2 %) 94.1 90.8 73.1 73.1
 Postmenopausal (n = 530, 11.0 %) 79.2 68.8 63.5 58.9
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HR-positive patients was found in patients receiving no 
adjuvant therapy at all with a 7-year OS rate of 73.1 % 
in premenopausal patients and 58.9 % in postmenopausal 
patients.
A Cox regression model (Table 7) provided further evi-
dence that HR-positive patients (n = 5410, 705 events) 
without ET showed lower OS than the control groups. 
Patients without ET but only CHT (HR 4.54, 95 % CI 
2.29–9.00, P < 0.001) and patients receiving no adjuvant 
therapy at all (HR 4.69, 95 % CI 2.43–9.06, P < 0.001) had 
the lowest OS.
Discussion
National and international guidelines strongly recommend 
the determination of HR-status in all patients with invasive 
breast cancer (Kreienberg et al. 2013; Untch et al. 2013). In 
HR-positive early breast cancer, adjuvant ET is considered 
as standard care. Using data from a high-quality popula-
tion-based regional cancer registry, we were able to analyze 
the quality of routine care.
HR determination steadily increased from 93.7 % in 
2000 to 99.7 % in 2012 and from 2009 on reached a con-
stant peak of 99.6 %. This demonstrates the high quality 
of HR assessment in the investigated area. Concerning 
HR-status, a slight increase in HR-positive breast cancer 
was observed from 82.1 % in 2000 to 88.1 % in 2012. In 
HR-positive breast cancer, the most common type was both 
ER- and PR-positive tumors with 71.6 % in premenopau-
sal patients and 74.6 % in postmenopausal patients. Inter-
laboratory consistency between the pathologies was given 
as the HR-status displayed to be homogenous. This fact 
can be expressed through the established quality assurance 
methods in the Tumor Centre Regensburg. The majority of 
breast cancers were scored as IRS 0 and IRS 12, whereas 
the IRSs lying in between were underrepresented in both 
ER and PR analyses. This distribution of IRS might be a 
function of tumor biology. In total, 73.9 % of patients 
were ER + PR + which represent Luminal A patients 
regarding the biology of tumors. These patients usually 
show high expression of ER and PR. By contrast, triple-
negative tumors, i.e., basal-like tumors, are characterized 
by HR-negativity, defined as ER−PR−. In total, 14.2 % 
Fig. 3  Kaplan–Meier plot of overall survival in years of premenopausal patients based on adjuvant therapy
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of our patients belong to this group. Analysis of systemic 
therapies showed that 85.3 % of all HR-positive patients 
received ET either alone or in combination with CHT and/
or trastuzumab which is in accordance with prior analyses 
of clinical cohort studies (Van Ewijk et al. 2013). How-
ever, nearly 10 % of HR-positive patients did not receive 
adjuvant therapy. This finding is comparable to data from 
a longitudinal study of breast cancer patients reported 
to the Metropolitan Detroit and Los Angeles SEER can-
cer registries: Of the 743 patients eligible for ET, 10.8 % 
never initiated therapy and 15.1 % started therapy but dis-
continued prematurely (Friese et al. 2013). Up to 5 % of 
HR-positive patients did not receive ET but only CHT. This 
might be due to lacking compliance of these patients. Gen-
erally, adjuvant therapy begins with CHT followed by ET. 
Presumably, these patients declined ET as they had to suf-
fer from many side effects from CHT. They might worry 
about further side effects from ET and the long duration of 
therapy.
The most frequently applied form of systemic treatment 
was a combination of CHT and ET in premenopausal and 
ET alone in postmenopausal patients. However, only post-
menopausal patients had a distinct benefit from the addi-
tion of CHT prior to ET. The Oxford Overview (Pritchard 
et al. 2012) similarly showed that there was a trend sug-
gesting greater CHT effect in the age 55- to 69-year group 
than in younger women. A Danish study from the popula-
tion-based database of the Danish Breast Cancer Coopera-
tive Group evaluated 6529 postmenopausal patients with 
ER-positive high-risk breast cancer and also concluded 
that only one quarter of postmenopausal patients are free 
of excess mortality when omitting adjuvant CHT (Ejlertsen 
et al. 2014). A 10-year update of the International Breast 
Cancer Study Group (IBCSG) Trial 11-93 demonstrated 
no evidence that adjuvant CHT provides additional disease 
control for premenopausal patients with lower-risk node-
positive endocrine-responsive breast cancer who receive 
adequate adjuvant ET (Thürlimann et al. 2009). The rea-
sons for these therapy effects in different age groups are 
probably multifactorial. A possible explanation might be 
a bias of selected therapies. It can be presumed that only 
patients without comorbidities, which are found more often 
Fig. 4  Kaplan–Meier plot of overall survival in years of postmenopausal patients based on adjuvant therapy
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in premenopausal patients, get an additional CHT. This 
observation has already been made in a previous study of 
our group (Inwald et al. 2014). Another explanation might 
be incompliant long-term use of ET especially in postmen-
opausal patients (Demissie et al. 2001). It has been shown 
that the adherence to adjuvant therapy in clinical practice is 
relatively poor, with up to 50 % of women not completing 
ET (Chlebowski et al. 2014). A study from an online breast 
cancer research registry showed that nonadherence among 
users was significantly associated with a lower financial 
status, a poorer relationship with the oncologist, and a prior 
switch in endocrine therapies (Stanton et al. 2014). How-
ever, low adherence to adjuvant ET increases the risk of 
death (Makubate et al. 2013). Nevertheless, there are some 
limitations of this population-based study: These data pri-
marily cover subnational or regional districts and might 
not reflect the entire population. The regional data might 
not be representative of international data due to regional 
variances, e.g., risk factors or access to early screening. 
However, the strength of the data is that it reflects routine 
healthcare provisions. Consequently, these data can be used 
to analyze the structures of patient-centered care.
Conclusions
We conclude that analysis of HR in patients with early 
breast cancer achieved very high quality in recent years 
due to implementation of guidelines and control mecha-
nisms. In line with current guidelines, the vast majority of 
HR-positive patients mostly received ET and this resulted 
in improved OS. Furthermore, our study showed differen-
tial effects of CHT and ET combination in premenopausal 
versus postmenopausal patients not previously described in 
a population-based cohort. In light of this positive finding, 
it is of major importance to track the minority of patients 
who did not receive appropriate therapy and to identify the 
reasons for this fatal deviation from current guidelines.
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